Clinical Study | Office of Clinical Research

A Phase III, Open-Label, Multicenter, Randomized Study Evaluating The Efficacy And Safety Of Atezolizumab (Mpdl3280a, Anti-Pd-L1 Antibody) In Combinat

Posted Date: May 15, 2019

Investigator: John Morris
Type of Study: Drug

The purpose of this study is to look at the effects, good or bad, of atezolizumab on you and the specific type of lung cancer (non-small cell lung cancer [NSCLC]) you have. Atezolizumab is an experimental drug, which means that health authorities have not approved atezolizumab for the treatment of

Criteria:

To Be Eligible To Participate, Patients Must Have Been Diagnosed With Stage Iv Squamous Non-Small Ce

Keywords:

Cancer, Go29437, Lung, Non Small Cell, Non Squamous

For More Information:

Uc Cancer Center
513-584-7698
kastla@uc.edu

Name*
First Last
Gender*
- Male
- Female
Age*
Phone*
Email*
How did you hear about us?*
Future Communication*
- By submitting this form, I am agreeing to receive future communication about participating in an upcoming research study.
CAPTCHA
This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
For questions regarding clinical studies at UC Health, contact us at ResearchStudies@UCHealth.com or (513) 245-3417.
List